Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» J&J's Zytiga slashes death risk by 38% in earlier-stage prostate cancer patients
J&J's Zytiga slashes death risk by 38% in earlier-stage prostate cancer patients
J&J's Zytiga slashes death risk by 38% in earlier-stage prostate cancer patients
Submitted by
admin
on June 3, 2017 - 9:23am
Source:
Fierce Pharma
News Tags:
JNJ
Zytiga
prostate cancer
ASCO 2017
Headline:
J&J's Zytiga slashes death risk by 38% in earlier-stage prostate cancer patients
Do Not Allow Advertisers to Use My Personal information
